Esperion Therapeutics, Inc. (ESPR)

Esperion Therapeutics Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Year	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013 - 2011
Net Income	-209.25	-233.66	-269.11	-143.55	-97.17	-201.81	-166.99	-74.98	-49.78	-36.38	Upgrade
Depreciation & Amortization	0.16	0.5	0.61	0.55	0.32	0.27	0.26	0.25	0.24	0.16	Upgrade
Share-Based Compensation	11.96	15.22	24.31	28.39	25.88	23.97	18.61	15.96	12.73	3.68	Upgrade
Other Operating Activities	61.64	43.12	-19.62	29.44	0.62	28.94	16.82	11.04	-1.33	0.52	Upgrade
Operating Cash Flow	-135.49	-174.83	-263.81	-85.18	-70.34	-148.64	-131.3	-47.73	-38.16	-32.02	Upgrade
Capital Expenditures	0	0	0	-0.87	-0.95	-0.15	-0.02	-0.09	-0.3	-0.86	Upgrade
Acquisitions	0	0	0	-12.5	0	0	0	0	0	0	Upgrade
Change in Investments	42.5	8.1	-50.48	34.73	65.18	140.6	-35.83	10.21	-159.77	-35.74	Upgrade
Investing Cash Flow	42.5	8.1	-50.48	21.36	64.23	140.45	-35.85	10.12	-160.07	-36.6	Upgrade
Share Issuance / Repurchase	65.95	90.85	222.45	-48.37	11.77	11.74	165.17	0.05	191.16	92.2	Upgrade
Debt Issued / Paid	-15.51	-58.02	46.09	250.09	124.42	-1.05	-1.71	-1.6	-0.64	4.84	Upgrade
Other Financing Activities	0.02	-0.22	-0.32	-	-	-	-	-	-	0.08	Upgrade
Financing Cash Flow	50.46	32.61	268.22	201.73	136.2	10.69	163.46	-1.56	190.52	97.12	Upgrade
Net Cash Flow	-42.53	-134.12	-46.07	137.9	130.09	2.51	-3.7	-39.17	-7.7	28.5	Upgrade
Free Cash Flow	-135.49	-174.83	-263.81	-86.05	-71.29	-148.79	-131.32	-47.82	-38.46	-32.88	Upgrade
Free Cash Flow Margin	-116.46%	-231.64%	-336.29%	-37.81%	-48.05%	-	-	-	-	-	Upgrade
Free Cash Flow Per Share	-1.31	-2.63	-9.13	-3.13	-2.63	-5.56	-5.49	-2.12	-1.75	-2.01	Upgrade

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).